gilteritinib
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Trial Timeline
Sep 22, 2025 → Dec 31, 2029
NCT ID
NCT07140016About gilteritinib
gilteritinib is a phase 1 stage product being developed by Astellas Pharma for Non-small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07140016. Target conditions include Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03409081 | Pre-clinical | Completed |
| NCT03070093 | Pre-clinical | Completed |
| NCT07140016 | Phase 1 | Recruiting |
| NCT06734585 | Pre-clinical | Completed |
| NCT04699877 | Phase 1 | Completed |
| NCT02561455 | Phase 1/2 | Completed |
| NCT02181660 | Phase 1 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)